Parenteral Drugs (India) (NSE:PDPL) EV-to-OCF: (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Parenteral Drugs (India)'s Enterprise Value is ₹1,173.07 Mil. Parenteral Drugs (India)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2022 was ₹0.00 Mil. Therefore, Parenteral Drugs (India)'s EV-to-OCF for today is .

The historical rank and industry rank for Parenteral Drugs (India)'s EV-to-OCF or its related term are showing as below:

NSE:PDPL's EV-to-OCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 10.725
* Ranked among companies with meaningful EV-to-OCF only.

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-01), Parenteral Drugs (India)'s stock price is ₹2.90. Parenteral Drugs (India)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was ₹-25.605. Therefore, Parenteral Drugs (India)'s PE Ratio (TTM) for today is At Loss.

Parenteral Drugs (India)  (NSE:PDPL) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Parenteral Drugs (India)'s PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.90/-25.605
=At Loss

Parenteral Drugs (India)'s share price for today is ₹2.90.
Parenteral Drugs (India)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-25.605.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Parenteral Drugs (India) EV-to-OCF Related Terms

Parenteral Drugs (India) EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) EV-to-OCF Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.21 1.81 8.49 -9,757.02 -244.57

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) EV-to-OCF Calculation

Parenteral Drugs (India)'s EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=1173.070/0
=

Parenteral Drugs (India)'s current Enterprise Value is ₹1,173.07 Mil.
Parenteral Drugs (India)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price